Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD70 monoclonal antibody SEA-CD70

A humanized, nonfucosylated monoclonal antibody directed against the human CD70 antigen, with potential immunomodulatory and antineoplastic activities. Upon administration, anti-CD70 monoclonal antibody sugar-engineered antibody (SEA)-CD70 selectivity targets and binds to the extracellular domain of CD70, which blocks CD70-mediated signaling. This may inhibit cellular proliferation and survival of CD70-expressing tumor cells, and may modulate the immune system to inhibit inflammatory signals and increase antigen-specific T-cell responses in the tumor microenvironment (TME). In addition, SEA-CD70 induces antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) against CD70-expressing tumor cells. CD70, a member of the tumor necrosis factor (TNF) family, is aberrantly expressed on malignant myeloid blasts while absent from healthy hematopoietic progenitor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:sugar-engineered antibody CD70
Code name:SEA CD70
SEA-CD70
SEACD70
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search